Paradigm Biocapital Advisors LP
- SEC CIK
- 0001855655
- Latest filing
- Aug 14, 2026
Holdings in Q1 2025
Holdings as of Mar 31, 2025, filed May 15, 2025. Long positions only; changes compare share counts with Q4 2024.
- Positions
- 27
- −1 vs. Q4 2024
- Portfolio value
- $2.17B
- −$701.7M (−24.4%) vs. Q4 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| NUVLNuvalent, Inc. | COM | 5,269,433 | $373.7M | 17.2% | −93,946−1.8% | Reduced | History |
| ACLXArcellx, Inc. | COMMON STOCK | 4,492,032 | $294.7M | 13.6% | +120,431+2.8% | Added | History |
| RVMDRevolution Medicines, Inc. | COM | 6,178,111 | $218.5M | 10.1% | −375,000−5.7% | Reduced | History |
| ONCBeOne Medicines Ltd. | ADR | 666,024 | $181.3M | 8.3% | +50,000+8.1% | Added | History |
| MRUSMerus N.V. | COM | 3,369,699 | $141.8M | 6.5% | +1,679,777+99.4% | Added | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 2,610,197 | $134.1M | 6.2% | +78,301+3.1% | Added | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 4,394,556 | $96.7M | 4.5% | −99,373−2.2% | Reduced | History |
| JANXJanux Therapeutics, Inc. | COM | 3,329,909 | $89.9M | 4.1% | −186,077−5.3% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 1,946,168 | $65.3M | 3.0% | +35,407+1.9% | Added | History |
| PCVXVaxcyte, Inc. | COM | 1,696,481 | $64.1M | 2.9% | +273,694+19.2% | Added | History |
| IRONDisc Medicine, Inc. | COM | 1,210,971 | $60.1M | 2.8% | −286,749−19.1% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 8,963,655 | $53.7M | 2.5% | +4,046,243+82.3% | Added | History |
| LENZLENZ Therapeutics, Inc. | COM | 1,511,932 | $38.9M | 1.8% | +741,477+96.2% | Added | History |
| APGEApogee Therapeutics, Inc. | COM | 961,707 | $35.9M | 1.7% | −322,059−25.1% | Reduced | History |
| ARGXArgenx SE | SPONSORED ADR | 59,679 | $35.3M | 1.6% | −421,626−87.6% | Reduced | History |
| CYTKCytokinetics Inc | COM NEW | 858,664 | $34.5M | 1.6% | +858,664 | New | History |
| INSMINSMED Inc | COM PAR $.01 | 451,359 | $34.4M | 1.6% | +451,359 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 2,127,205 | $34.3M | 1.6% | +600,000+39.3% | Added | History |
| MTSRMetsera, Inc. | COM | 1,191,462 | $32.4M | 1.5% | +1,191,462 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,095,079 | $28.2M | 1.3% | +275,000+15.1% | Added | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 6,741,172 | $25.3M | 1.2% | −563,798−7.7% | Reduced | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 627,423 | $24.5M | 1.1% | −1,144,788−64.6% | Reduced | History |
| ARQTArcutis Biotherapeutics, Inc. | COM | 1,465,334 | $22.9M | 1.1% | +1,465,334 | New | History |
| YMABY-mAbs Therapeutics, Inc. | COM | 4,236,346 | $18.8M | 0.9% | 00.0% | Unchanged | History |
| ERASErasca, Inc. | COM | 10,802,354 | $14.8M | 0.7% | +50,000+0.5% | Added | History |
| OCULOcular Therapeutix, Inc | COM | 1,314,018 | $9.63M | 0.4% | +1,314,018 | New | History |
| IMTXImmatics N.V. | SHS | 1,907,108 | $8.60M | 0.4% | −3,507,301−64.8% | Reduced | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| EWTXEdgewise Therapeutics, Inc. | COM | – | $11.0M |
Sold out since Q4 2024 (6)
Positions held at the end of Q4 2024 that are gone from this filing.
| Security | Class | Shares in Q4 2024 | Value in Q4 2024 | % of portfolio in Q4 2024 | History |
|---|---|---|---|---|---|
| VERAVera Therapeutics, Inc. | CL A | 1,437,339 | $60.8M | 2.1% | History |
| PLRXPliant Therapeutics, Inc. | COM | 3,197,050 | $42.1M | 1.5% | History |
| TECXTectonic Therapeutic, Inc. | COM | 485,105 | $22.4M | 0.8% | History |
| SRRKScholar Rock Holding Corp | COM | 400,000 | $17.3M | 0.6% | History |
| ORKAOruka Therapeutics, Inc. | COM | 819,660 | $15.9M | 0.6% | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 276,439 | $9.08M | 0.3% | History |